Dr. Marco Bonizzato receives the 2022 Turnbull-Tator Award for his groundbreaking publication on an intracortical neuroprosthesis that improves recovery of leg control after spinal cord injury. The award supports two trainees in his lab to develop a neurorehabilitation platform for neuroprosthetic therapies.
Ten researchers have received $100,000 grants to support clinical stroke research in Canada, aiming to reduce the burden of stroke, prevent recurrence, and improve patient outcomes. The new program is part of a larger initiative by Brain Canada, Heart & Stroke, and the Canadian Stroke Consortium.
The Brain Canada Foundation and the Canadian Institutes of Health Research have invested $663,000 in two groundbreaking projects: REBALANCE and HiCALS. REBALANCE explores focused ultrasound as a potential treatment for Alzheimer's disease, while HiCALS investigates the link between high-fat diets and ALS survival.
Twenty early-career researchers from Canada will receive funding for their innovative projects on brain disorders, including epilepsy, depression, and multiple sclerosis. The grants aim to reduce the social and economic burden of these conditions through prevention, early diagnosis, and treatment.
Dr. Aaron Phillips received the 2021 Turnbull-Tator Award for his innovative research on neuroprosthetic baroreflex controls after spinal cord injury. He aims to develop a widely available therapy to improve blood pressure stability and quality of life for those affected.
The ALS Canada Research Program has awarded nine Discovery Grants to investigate critical areas of disease processes and clinical care. The grants will support fundamental laboratory research, biomarker studies, and clinical trials.
Two Canadian-led brain research teams will receive funding to develop and validate new measures of dementia care and outcomes, addressing existing measurement gaps. The projects aim to improve care practices and desired outcomes for individuals with dementia, in collaboration with the Alzheimer's Association and Brain Canada.
A new study has made an Alzheimer's disease biomarker test available to all Canadians, enabling doctors to accurately diagnose the disease even when mild symptoms are present. The test aims to improve care and support for individuals living with Alzheimer's disease and their families.
Dr. Mario Masellis' international team is receiving $320,198 in funding to examine the interplay between genetic, demographic, and cardiovascular factors on dementia risk. The project aims to improve management and prevention of dementia, ultimately reducing its impact worldwide.